Alkermes accused in US court maintaining illegal monopoly for anti-opioid treatment
MLex Summary: Value Drug Company has filed a US antitrust complaint accusing Alkermes of illegally prolonging its monopoly in the injectable naltrexone market and protecting its brand Vivitrol monopoly profits from...To view the full article, register now.
Already a subscriber? Click here to view full article